Capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer: Experience of the oncology department of the university hospital of Oran, Algeria

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide. It in elderly people, with a median age at diagnosis of 70 years. The y is to explore whether G8 questionnaire may be helpful to decide the for older colorectal cancer patients.October 2015 to June 2017, we prospectively screened 137 !75-yearswith CRC who were referred for chemotherapy. In our center, underwent oncogeriatric screening for a comprehensive geriatric assessis positive in ! 85-years-old patients or 75-85-years-old patients with criteria: G8 scale,14, Pfeiffer test >2, Barthel index <90 and positive scale. In addition, age, comorbidity and ECOG performance status account for final treatment decision. We hypothesize G8 vulnerability with toxicity and may help guiding treatment decisions.age of screened patients was 80.44 years (75.1-88.9). The most frewas colon cancer (71.8%) followed by rectal cancer (28.2%). 47.4% of atic disease. G8 detected vulnerability (<14 score) in 62% of was more frequently dismissed in these fragile patients (45.9% ts vs 28.6 of G8!14 patients). Overall, 67 patients received chemother-70.1%, FOLFOX 19.4%, FOLFIRI 1.5%, clinical trial treatment 9%). for those patients who initiated treatment at full-dose intensity, a dose needed afterwards in 76% of G8<14 patients vs 28.6% of G8!14 patients e of chemotherapy also significantly differed, with any grade 3/4 50% vs 20% of patients respectively (p ¼ 0.041), and a higher risk ratio such toxicity for G8<14 patients (Risk ratio 4, 95% CI 0.995-16.074).tion of treatment due to toxicity was needed in 15.2% vs 6.7% of ly (p ¼ 0.43). There were no toxic deaths. <14 score correlates with a greater probability of presenting relevant n, G8 questionnaire identifies a group of patients who more likely n during treatment. For this reason, G8 appears to be a helpful for treatment decision-making in elderly colorectal cancer patients.SEER analysis of increasing disparities in age-related cause survival (CSS) among patients with colorectal cancer

Effect of capecitabine combined with irinotecan on the safety of colon cancer treatment, patients’ adverse reactions and quality of life

“…Moreover, irinotecan, a popular drug for colon cancer, effectively facilitates enzymatic activity involved in metabolism of capecitabine. Therefore, these two drugs may exert good synergistic effects [4][5][6]. Based on this, the present study was on the influence of combined use of capecitabine and irinotecan in the treatment of 120 colon cancer subjects.…”